BRIEF-European regulators recommends approval of Gilead's new HIV treatment By: Reuters: Company News April 29, 2016 at 07:32 AM EDT * EU Medicines Agency recommends approval of Biogen Inc and AbbVie Inc's daclizumab to treat multiple sclerosis Read More >> Related Stocks: AbbVie Allergan Plc Biogen Idec Gilead Sciences